Neimeth major shareholder buys additional 74.7 million shares for N448 million
A major shareholder in Neimeth International Pharmaceuticals Plc, Clinoscope Services Limited, has purchased an additional 74.7 million ordinary shares in the pharmaceutical company for approximately N448.36 million. The post Neimeth major shareholder buys additional 74.7 million shares for N448 million appeared first on Nairametrics .
Major shareholder Clinoscope Services Limited has acquired an additional 74.7 million shares in Neimeth International Pharmaceuticals Plc for N448.36 million, according to an insider notification filed with the Nigerian Exchange on November 13, 2026. The transaction took place on November 10, 2026, in Lagos at a price of N6 per share.
Clinoscope Services Limited's Secretary, Chinenye S. Adekanmbi, signed the disclosure. However, the filing did not disclose the number of shares Clinoscope Services Limited held before this purchase or the percentage of the company it now owns. This stock purchase comes as Neimeth International Pharmaceuticals Plc returns to profitability, recording a pre-tax profit of N1.49 billion for the year ended December 31, 2025, after incurring a loss of N854.43 million in the previous year.
Despite the earnings recovery, the company still grapples with financing and liquidity issues, with its total external debt rising to N9.68 billion from N5.36 billion and cash and cash equivalents falling to N1.61 billion from N2.15 billion. In June 2026, Neimeth shareholders approved a capital-raising mandate of N30 billion, raising the total approved fundraising ceiling to N50 billion.
This includes potential expansion of its pharmaceutical product lines. As of November 13, 2026, Neimeth shares were trading at N7.20 on the NGX, marking a 24.14% gain year-to-date.
Written by urgent.news from Nairametrics's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
